Impact of PSMA PET Staging on Initial Treatment in Newly Diagnosed Prostate Cancer [0.03%]
PSMA PET 显像对新诊断前列腺癌初始治疗的影响
Sean R Miller,Dana H Chung,Rachel T Gonzalez et al.
Sean R Miller et al.
Prostate-specific membrane antigen (PSMA) PET/CT has become a common staging modality for newly diagnosed high-risk and unfavorable intermediate-risk prostate cancer after showing improved sensitivity and specificity compared with conventio...
PET Never Lies: Healthy Organ Uptake Beyond Tumor Expression in Theranostic Applications [0.03%]
PET不会说谎：治疗诊断应用中超出肿瘤表达的正常器官摄取
Fabrizia Gelardi,Cristiano Pini,Martina Sollini et al.
Fabrizia Gelardi et al.
Evaluating Interim Progression: First Posttherapy 177Lu-PSMA SPECT/CT Relative to Baseline PSMA PET/CT [0.03%]
interim progression：首次 posttherapy 177Lu-PSMA SPECT/CT 相对于基线PSMA PET/CT的评估
Ashwin Singh Parihar,Farrokh Dehdashti,Niharika Pant et al.
Ashwin Singh Parihar et al.
Prostate Cancer Working Group 4 recommends using prostate-specific membrane antigen (PSMA) PET for response assessment of patients with androgen pathway receptor modulator-resistant prostate cancer treated with 177Lu-PSMA-617. For that purp...
Evaluation of 9-Minute Dual-Energy Peak Time-Reduced 360° CZT Total-Body [177Lu]Lu-PSMA SPECT/CT Imaging with Comparisons to [68Ga]Ga-PSMA PET [0.03%]
与[68Ga]Ga-PSMA PET相比，[177Lu]Lu-PSMA CZT SPECT/CT全身成像的9分钟双能量峰值时间减少360度评估研究报告
Caroline Boursier,Sébastien Heyer,Abdelaali Zouaoui et al.
Caroline Boursier et al.
Eighteen-minute 360° cadmium zinc telluride (CZT) total-body 177Lu-labeled SPECT acquisitions on the single 113-keV 177Lu photopeak (SP-18) have been reported to be suitable for monitoring [177Lu]Lu-PSMA therapy. This study evaluated dual-...
Outcome Prediction After [177Lu]Lu-PSMA I&T in Metastatic Castration-Resistant Prostate Cancer: External Validation of a [68Ga]Ga-PSMA-11 PET-Based Model with [18F]F-Flotufolastat [0.03%]
[177Lu]Lu-PSMA I&T 治疗后转移性去势抵抗性前列腺癌的疗效预测：基于[68Ga]Ga-PSMA-11 PET模型的外部验证和[18F]F-Flotufolastat的研究
Amir Karimzadeh,Cornelia Fütterer,Kimberley Hansen et al.
Amir Karimzadeh et al.
177Lu-prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy is an established treatment for metastatic castration-resistant prostate cancer, though responses vary. A prognostic model using [68Ga]Ga-PSMA-11 PET-deriv...
Reply: PET Never Lies: Healthy Organ Uptake Beyond Tumor Expression in Theranostic Applications [0.03%]
PET不会说谎：治疗诊断应用中超出肿瘤表达的健康器官摄取
Wenjia Zhu,Li Huo
Wenjia Zhu
Clinical Impact and Dynamics of Clonal Hematopoiesis with 177Lu-PSMA-617 Therapy in Advanced Prostate Cancer [0.03%]
177Lu-PSMA-617治疗前列腺癌并克隆性血细胞增多的临床影响及动态监测
Praful Ravi,Caiwei Zhong,Kimberly J Perez et al.
Praful Ravi et al.
The prevalence, clinical impact, and clonal dynamics of clonal hematopoiesis (CH) in patients receiving 177Lu-PSMA-617 (LuPSMA) for metastatic castration-resistant prostate cancer (mCRPC) are unknown. Methods: Targeted next-generation seque...
Combining an αvβ6-Targeted 177Lu-Based Peptide Receptor Radionuclide Therapy with Olaparib to Boost Therapeutic Efficacy in Pancreatic Cancer [0.03%]
结合αvβ6靶向的177Lu基肽受体放射性核素疗法与奥拉帕利以增强胰腺癌治疗效果
Tanushree Ganguly,Rebecca E Harris,Sven H Hausner et al.
Tanushree Ganguly et al.
Pancreatic ductal adenocarcinoma is one of the most lethal malignances worldwide, and there remains an urgent need for more effective and less toxic treatment strategies. Integrin αvβ6 is a cell-surface receptor that is overexpressed in s...
Update to "Renal and Multiorgan Safety of 177Lu-PSMA-617 in Patients with Metastatic Castration-Resistant Prostate Cancer in the VISION Dosimetry Substudy" [0.03%]
关于“在VISION剂量学亚研究中转移性去势抵抗性前列腺癌患者中177Lu-PSMA-617的肾和多器官安全性”的更新
Ken Herrmann,Kambiz Rahbar,Matthias Eiber et al.
Ken Herrmann et al.
2025 SNMMI Basic Sciences Summary Session Highlight Lectures: Physics, Instrumentation, and Data Sciences [0.03%]
2025 SNMMI基础科学概要会议亮点讲座：物理、仪器和数据科学
Chi Liu,Ling-Jian Meng,Jinyi Qi et al.
Chi Liu et al.